Xenetic Biosciences Files 8-K on Financials

TL;DR

XBIO filed its 8-K. Financials and operations update.

AI Summary

On March 22, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as General Sales & Leasing, Inc. and GENERAL AIRCRAFT INC., is incorporated in Nevada and operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides investors with an update on Xenetic Biosciences' financial condition and operational performance, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not contain new material events or significant risk disclosures.

Key Players & Entities

• Xenetic Biosciences, Inc. (company) — Registrant
• General Sales & Leasing, Inc. (company) — Former Company Name
• GENERAL AIRCRAFT INC. (company) — Former Company Name
• Nevada (jurisdiction) — State of Incorporation
• March 22, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq

Filing Documents

• xenetic_8k.htm (8-K) — 32KB
• xenetic_ex9901.htm (EX-99.1) — 15KB
• image_001.jpg (GRAPHIC) — 3KB
• 0001683168-24-001606.txt ( ) — 267KB
• xbio-20240322.xsd (EX-101.SCH) — 4KB
• xbio-20240322_def.xml (EX-101.DEF) — 26KB
• xbio-20240322_lab.xml (EX-101.LAB) — 36KB
• xbio-20240322_pre.xml (EX-101.PRE) — 25KB
• xenetic_8k_htm.xml (XML) — 5KB

02

Item 2.02. Results of Operations and Financial Condition. On March 22, 2024, Xenetic Biosciences, Inc. (the "Company") issued a press release announcing results for the year ended December 31, 2023 and providing a corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Form 8-K, including the press release, contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K, including the press release, other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements or results to differ materially from the activities and results anticipated in forward-looking in the Company's reports filed with the Securities and Exchange Commission ("SEC"), including the Company's annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak and, geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this Form 8-K, including the press re

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 22, 2024 pertaining to the financial results of the Company for the year ended December 31, 2023 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: March 22, 2024 Name: James Parslow Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR